GSK Gains FDA Approval for Breakthrough Cancer Immunotherapy

2026-10-20 companies

London, Tuesday, 20 October 2026.
GSK secured landmark US approval for its immunotherapy Jemperli, showing a 76% tumor-free rate in rectal cancer trial patients while trading at a discount compared to industry peers.

Regulatory Milestone and Clinical Data

GSK plc (GSK:LON) secured a significant regulatory victory on 19 October 2026, when the US Food and Drug Administration granted accelerated approval to Jemperli (dostarlimab) for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer [8]. This approval marks the first immunotherapy licensed for this specific indication, offering an alternative to standard treatments involving chemotherapy, radiation, and surgery which carry risks of bowel and urinary dysfunction [8]. The decision was grounded in data from the phase II AZUR-1 trial, where 76% of patients showed no evidence of cancer one year or more post-treatment [8]. Specifically, 68% of evaluable patients achieved a sustained clinical complete response at 12 months, highlighting the drug’s potential to alter treatment protocols for the 5% to 10% of rectal cancer cases characterized by MSI-H/dMMR biomarkers [8]. Tony Wood, Chief Scientific Officer at GSK, noted that this approval represents an important step towards more personalised care, moving away from decades of reliance on traditional invasive methods [8]. The company’s oncology strategy aims to expand beyond blood and women’s cancers into gastrointestinal solid tumors, with pipeline programs including antibody-drug conjugates targeting B7-H3 and B7-H4 [8].

Market Performance and Trading Metrics

Following the regulatory news, GSK shares traded under scrutiny on the London Stock Exchange on 20 October 2026, closing at GBX 1,865.50, a rise of 0.57% from the previous session [1]. This performance followed a decline to GBX 1,855.00 on 19 October 2026, representing a net price change of 10.5 GBX over the two-day period [1]. Intraday data indicated the stock was trading at GBX 1,862.47 as of 10:53 am BST on 20 October, reflecting delayed market data common in cross-border trading [5]. The company’s stock has delivered a 59.1% share price gain over the five-year period leading up to 18 October 2026, prompting analysis on whether the current valuation aligns with earnings potential [7]. Geographic revenue concentration remains heavily skewed, with the United States accounting for 51.6% of revenue, followed by Europe at 21% and other regions at 25.3% [1]. This exposure to the US market underscores the significance of the FDA approval for Jemperli, as domestic pharmaceutical sales constitute the largest segment of the company’s net sales distribution [1].

Valuation Analysis and Strategic Outlook

Investors are currently weighing GSK’s valuation metrics against sector peers, with the company’s Price-to-Earnings (P/E) ratio standing at approximately 15.5x as of 18 October 2026 [7]. This figure represents a discount compared to the wider pharmaceuticals sector average of 21.6x, suggesting a potential undervaluation of 28.241 percent relative to the industry benchmark [7]. However, market narratives remain divided; a bull case suggests the stock is 14% undervalued driven by long-acting HIV injectables, while a bear case argues it could be 28% overvalued due to a 9% decline in General Medicines sales in the second quarter of 2026 [7]. Strategic restructuring efforts are underway, including job cuts in Belgium and an investment exceeding $800 million for biopharma expansion in Pennsylvania, USA [7]. Additionally, recent trial data for the Embold study in small cell lung cancer showed an objective response rate of 61% at an 8 mg/kg dose, further diversifying the pipeline beyond the recent rectal cancer approval [6]. As of 20 October 2026, the FTSE 100 was expected to open down 0.2%, reflecting broader macroeconomic pressures impacting defensive equities in late 2026 [6].

Sources

Pharmaceuticals GSK